Additionally, in animal models of MS deletion of CerS2 in blood cells resulted in a delay in the onset of symptoms due to reduced infiltration of immune cells into the CNS [117], whereas deletion of CerS6 resulted in an increment in the infiltration [116]. Here, CERS2 is linked to myeloid sarcoma.